# A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Source: https://onco.cc/trials/nct07221500/  
OnCo record `nct07221500` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Bexobrutideg in chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting.

## Summary

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) is a phase 2 interventional study registered as NCT07221500 by Nurix Therapeutics, Inc., with 100 participants planned, started 2025-10-15 and due to reach its primary completion in 2028-01. Interventions recorded: NX-5948.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07221500
- Phase: 2
- Setting: A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
- Sponsor: Nurix Therapeutics, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07221500: https://clinicaltrials.gov/study/NCT07221500

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Bexobrutideg](https://onco.cc/drugs/bexobrutideg/)
- companies: [Nurix Therapeutics](https://onco.cc/companies/nurix/)

---
JSON: https://onco.cc/api/v1/entities/nct07221500.json